Kesi Kindle-Suersin, MD
Geriatric Medicine · Winston Salem, NCNPI 1528035268
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 83 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $851 and has fallen 96.6% since, to $29 in 2024. Among geriatric medicine clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 83 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$300
- AstraZeneca$186
- GSK$89
- Sanofi-aventis U.S. LLC$88
- Boehringer Ingelheim$77
- Lilly USA, LLC$73
- plus $442 from 16 others
What the payments were for
- Food & beverage$1,249100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 21 | $300 |
| AstraZeneca | 13 | $186 |
| GSK | 6 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $88 |
| Boehringer Ingelheim | 5 | $77 |
| Lilly USA, LLC | 5 | $73 |
| Astellas Pharma US Inc | 3 | $55 |
| Novartis | 4 | $55 |
| Corium, LLC | 4 | $53 |
| Johnson & Johnson | 2 | $34 |
| Mylan Specialty L.p. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| AbbVie | 1 | $25 |
| Pfizer | 2 | $25 |
| Corcept Therapeutics | 1 | $20 |
| Amgen | 1 | $20 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Exact Sciences | 1 | $17 |
| Bayer | 1 | $16 |
| Merck | 1 | $14 |
How this compares
$1,255 in reported general payments places this provider in the 90th percentile of 138 geriatric medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 119 | $177,300 |
| OzempicSemaglutide | 106 | $170,719 |
| EliquisApixaban | 105 | $117,690 |
| JardianceEmpagliflozin | 84 | $115,375 |
| FarxigaDapagliflozin Propanediol | 53 | $71,053 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 45 | $55,497 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 49 | $48,105 |
| LinzessLinaclotide | 38 | $35,894 |
| SymbicortBudesonide/Formoterol Fumarate | 78 | $24,442 |
| RybelsusSemaglutide | 16 | $23,463 |
| MyrbetriqMirabegron | 22 | $23,067 |
| Tresiba Flextouch U-100Insulin Degludec | 38 | $22,760 |
| XareltoRivaroxaban | 17 | $21,931 |
| Spiriva RespimatTiotropium Bromide | 23 | $21,893 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $18,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $300 | $194,182122 claims |
| Lilly USA, LLCMounjaro | $73 | $177,300119 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $186 | $150,991176 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $77 | $137,268107 claims |
| PfizerEliquis | $25 | $117,690105 claims |
| GSKTrelegy Ellipta | $89 | $48,10549 claims |
| AbbVieLinzess, Synthroid | $25 | $37,46649 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $55 | $29,80534 claims |
| Johnson & JohnsonXarelto | $34 | $21,93117 claims |
| NovartisEntresto | $55 | $14,58913 claims |
| MerckJanumet Xr | $14 | $8,82313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 138 geriatric medicine providers in North Carolina.
Other geriatric medicine in Winston Salem
- Jeff WilliamsonWinston Salem$1K
- Henry TrippWinston Salem$638
- Rachel MartinWinston Salem$522
- Jamehl ShegogWinston Salem$366
- Maria-Dorina SevillaWinston Salem$302
- Kathryn CallahanWinston Salem$197
- Holly CowardWinston Salem$144
- Carl GreyWinston Salem$114
- Robert StewartDurham$103K
- Mary Busby WhiteheadChapel Hill$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.